Farallon Capital Partners, L.P. - Significant Ownership

Signature - Title
/s/ Hannah E. Dunn - Hannah E. Dunn, Managing Member of its General Partner
Location
San Francisco, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Farallon Capital Partners, L.P..

Email me when Farallon Capital Partners, L.P. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Farallon Capital Partners, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PTGX Protagonist Therapeutics, Inc. Common Stock, par value $0.00001 per share (the "Shares") 9.99% $265M 5.96M Dapice Joshua J. Dec 31, 2024
BEAM Beam Therapeutics Inc. Common Stock, par value $0.01 per share (the "Shares") 9.99% $197M $34.2M 9.97M +21% Dapice Joshua J. Mar 31, 2025
SVRA Savara Inc. Common Stock, par value $0.001 per share (the "Shares") 9.99% $58.2M 18.3M Dapice Joshua J. Dec 31, 2024
LQDA Liquidia Corporation Common Stock, par value $0.001 per share (the "Shares") 9.95% $195M $39.4M 8.57M +25.4% Dapice Joshua J. Sep 30, 2025
AGIO AGIOS PHARMACEUTICALS, INC. Common Stock, par value $0.001 per share (the "Shares") 9.9% $166M 5.67M Dapice Joshua J. Dec 31, 2024
ENTA ENANTA PHARMACEUTICALS INC Common Stock, par value $0.01 per share (the "Shares") 9.9% $12M 2.11M Dapice Joshua J. Dec 31, 2024
TNGX Tango Therapeutics, Inc. Common stock, par value $0.001 per share (the "Shares") 9.7% $90.4M $13.4M 10.8M +17.5% Dapice Joshua J. Sep 30, 2025
BBNX Beta Bionics, Inc. Common Stock, $0.0001 par value per share (the "Shares") 9.7% $57M 4.2M Dapice Joshua J. Jun 30, 2025
RVMD Revolution Medicines, Inc. Common Stock, par value $0.0001 per share (the "Shares") 7.9% $512M $74.5M 13.3M +17% Dapice Joshua J. Dec 31, 2024
ASMB Assembly Biosciences, Inc. Common Stock, par value $0.001 per shares (the "Shares") 7.3% $20.7M 1.14M Dapice Joshua J. Aug 8, 2025
EXEL EXELIXIS, INC. Common Stock, par value $0.001 per share (the "Shares") 6.8% $718M -$185M 18.6M -20.5% Dapice Joshua J. May 16, 2025
MEHCQ 23andMe Holding Co. Class A Common Stock, par value $0.0001 per share 6.2% $3.88M 1.27M Dapice Joshua J. Jun 13, 2025
CRNX Crinetics Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (the "Shares") 6% $164M 5.63M Dapice Joshua J. Aug 29, 2025
GRAL GRAIL, Inc. Common Stock, par value $0.001 per share (the "Shares") 5.5% $199M $21.1M 2.18M +11.9% Dapice Joshua J. Nov 17, 2025
CATX Lantheus Holdings, Inc. Common Stock, par value $0.01 per share (the "Shares") 5.1% -$142M 3.48M -42.3% Dapice Joshua J. Sep 30, 2025
ARMK Aramark Common Stock, Par Value $0.01 per share (the "Shares") 4.9% $563M -$146M 12.9M -20.6% Dapice Joshua J. Jun 30, 2025
NYT The New York Times Company Class A Common Stock, par value $0.10 per share (the "Shares") 3.5% $314M -$190M 5.61M -37.8% Dapice Joshua J. Jun 30, 2025
FBRX Forte Biosciences, Inc. Common Stock, par value $0.001 per share (the "Shares") 3.4% $12.1K 221K Dapice Joshua J. Dec 31, 2024
ANNA AleAnna, Inc. Class A common stock, par value $0.0001 per share (the "Shares") 2.6% $12.7M 1.07M Dapice Joshua J. Dec 31, 2024
ELEV Elevation Oncology, Inc. Common Stock, Par Value $0.0001 per share (the "Shares") 0% $0 -$1.31M 0 -100% Farallon Capital Partners, L.P. Mar 31, 2025

Schedules 13D/G Reported by Farallon Capital Partners, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.